Head-to-head evidence
certolizumab pegol vs SAR441566
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT03357471 · Phase 3 · completed
Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
SAR441566
Developed by Sanofi
NCT06073093 · Phase 2 · completed
The study randomized 264 participants to four SAR441566 dose regimens or placebo and used triple masking of participants, investigators, and outcome assessors. Its primary endpoint was the clinical ACR20 response at week 12, but results have not been posted, so whether the endpoint was met or missed cannot be assessed.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · SAR441566's landscape